CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Mabylon is developing human-derived antibodies to target neurodegenerative diseases, leveraging a unique screening platform to identify specific antibodies from human blood samples. The project aims to address unmet medical needs in treating conditions like amyotrophic lateral sclerosis and frontotemporal dementia.
Neurodegenerative diseases are one of the disease fields with the highest unmet need.
Decades of research have been invested in finding cures, however almost none have been successful.
Antibodies have great therapeutic potential to treat these diseases as they are broadly applicable to specifically target different aspects of disease-causing processes.
However, most of current non-human antibodies are limited by side-effects and a lack of specificity.
Human-derived antibodies, derived from human…
MABYLON AG
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
